- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
NeoRx settles investor lawsuits
Monoclonal antibody developer NeoRx of Seattle last month settled a lawsuit filed against it by shareholders.The litigation was related to a public stock offering made byNeoRx in December 1993 (SCAN 6/15/94). The settlement is for stockor a combination
Monoclonal antibody developer NeoRx of Seattle last month settled a lawsuit filed against it by shareholders.The litigation was related to a public stock offering made byNeoRx in December 1993 (SCAN 6/15/94). The settlement is for stockor a combination of stock and cash worth $1.5 million. A substantialportion of the settlement will be covered by insurance, the companysaid.
NeoRx last month also reported its financial results for 1994(end-December). The company reported a net loss of $11.1 millionon revenues of $1.6 million for the year, compared to a net lossof $8.5 million and revenues of $3.7 million in 1993.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Could a Newly FDA-Cleared C-Arm Device Bolster Efficiency for Interventional Radiologists?
April 22nd 2024In addition to advanced imaging quality and dose efficiency, the Philips Zenition 30 mobile C-arm device emphasizes personalized user profiles and automated customization to help reduce procedure time.
